A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Everolimus (Primary) ; Trastuzumab; Vinorelbine
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 07 May 2018 Status changed from active, no longer recruiting to completed.
- 26 Jun 2017 Planned End Date changed from 19 May 2017 to 4 May 2019.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology